JPRN-C000000175已完成未知
Pegylated IFN alpha-2b/Ribavirin therapy for chronic hepatitis C with genotype Ib, high titer-analysis with viral clearance. - GLSG PEG/Rib 2005
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine0 个研究点目标入组 250 人开始时间: 2005年9月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 250
研究概览
简要总结
ot significant change
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Complicated with other liver diseases such as autoimmune hepatitis and alcoholic liver injury. (2)Liver cirrhosis, hepatic failure. (3)Drug allergy for IFN or ribavirin. (4)Drug allergy for vaccine. (5)Administration of other anti-viral or immunomodulatory treatment. (6)Pregnancy. (7)Depression. (8)Complicated with autoimmune disorders.
研究者
相似试验
已完成
不适用
The combination therapy of PEG-IFN alpha 2b, Ribavirin and Telaprevir for the patients with chronic hepatitis C:the study for treatment duration by response guided therapy and prediction of efficacy by gene analysis in Japan.chronic hepatitis CJPRN-UMIN000018971agoya university500
已完成
不适用
Peg-IFN-alfa-2b/Ribavirin combination therapy for chronic hepatitis C patients: Effectiveness prediction by gene analysis and efficacy with Fluvastatin combinatiochronic hepatitis CJPRN-UMIN000008196Kanazawa University200
招募中
不适用
Peg-IFN-alfa2b/Ribavirin/Telaprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and Duration of therapyJPRN-UMIN000008198Kanazawa University200
招募中
不适用
Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and duration of therapychronic hepatitis CJPRN-UMIN000016639Kanazawa University100
已完成
不适用
Peg-IFN-alfa2a/Ribavirin combination therapy for chronic hepatitis C with serogroup1 and high viral load: analysis of IL28B gene and efficacy of vitamin D combinatiochronic hepatitis CJPRN-UMIN000008197Kanazawa university200